In conclusion, our findings shed new light on the pivotal role of CD8+ T cells in the white matter injury after cerebral ischemic stroke and we propose that IL‐2mAb may be an intriguing therapeutic strategy for long‐term neuroprotection against demyelination after stroke. The gene discussed is CD8A; the disease is stroke disorder.